Atopic dermatitis management with tacrolimus ointment (Protopic®)

References

• Hanifin JM, Rajka G, Diagnostic features of atopic dermatitis. Acta Dermatovener(Stockh) (1980) 92: S44-7.
   Google Scholar
• Leung DY, Hanifin JM, Charlesworth EN et al, Disease management of atopic dermatitis: a practice parameter. Ann Allergy Asthma Immunol (1997) 79: 197-211.
   Google Scholar
• Kino T, Hatanaka H. Hashimoto M et al, FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. j Antibiot(Tokyo) (1987) 40: 1249-55.
   Google Scholar
• Fleischer AB, Jr, Treatment of atopic dermatitis: role of tacrolimus ointment as a topical noncorticosteroidaltherapy. J Allergy Clin Immunol (1999) 104: S126- 30.
   Google Scholar
• Leung DYM, Atopic dermatitis: new insights and opportunities for therapeutic intervention. J Allergy Clin 'minimal (2000) 105: 860-76.
   Google Scholar
• Wollenberg A, Sharma S, von Bubnoff D et al. Topical tacrolimus(FK506)leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis. J Allergy Clin!minimal (2001) 107: 519-25.
   Google Scholar
• Diepgen TL,Is the prevalence of atopic dermatitis increasing? In: Williams HC, cd. Atopic dermatitis. The epidemiology, causes and prevention of utopie eczema. Cambridge: Cambridge University Press, 2000: 96-109.
   Google Scholar
• Zheng PS, Lavker RM, Lehmann P, Kligman AM, Morphologic investigations on the rebound phenomenon after corticosteroid-induced atrophy in human skin, J Invest Dermatol (1984) 82: 345-52.
   Google Scholar
• Goerz G, Lehmann P, Topical treatment with cortico-steroids. In: Ruzicka T, Ring J, Przybilla 11, eds. Handbook of Atopic Eczema. Berlin: Springer Verlag, 1991: 375-90.
   Google Scholar
• Brazzini 13, Pimpinelli N, New and established topical corticosteroids in dermatology: clinical pharmacology and therapeutic use. Am J Clin Dermatol (2002) 3: 47-58.
   Google Scholar
• Hanifin JM, Ling MR, Langley R, Breneman D, Rafal E, and the Tacrolimus Ointment Study Group, Tacrolimusointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. J Am Acad Dermatol (2001) 44: S28-38.
   Google Scholar
• Palter A, Eichenfield LF, Leung DY, Stewart D, Appell M, and the Tacrolimus Ointment Study Group, A 12-week study of tacrolimusointment for the treatment of atopic dermatitis in pediatric patients. J Am Atyid Dermatol (2001) 44: S47-57.
   Google Scholar
• Reitamo S, Rustin M. Ruzicka T et al, for the European Tacrolimus Ointment Study Group, Efficacy and safety of tacrolimus ointment compared with hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 109: 547-55.
   Google Scholar
• Reitamo S, van Leent EJM, Ho V et al, for the European/ Canadian Tacrolimus Ointment Study Group, Efficacy and safety of tacrolimus ointment codtared with hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Imintinol (2002) 109: 539-46.
   Google Scholar
• Reitamo S, for the European Tacrolimus Ointment Study Group, 0.1%Tacrolimus ointment is significantly more efficacious than a steroid regimen in adults with moderate to severe atopic dermatitis. 12th Congress of the European Academy of Dermatology and Venereology, St. Julian's, Malta, 27 February-1 March: Poster presentation PP1-28.
   Google Scholar
• Reitamo S, Wollenberg A, Schopf E et al, for the European Tacrolimus Ointment Study Group, Safety and efficacy of 1 year of tacrolimus ointment monotherapyin adults with atopic dermatitis. Arch Dermatol (2000) 136: 999-1006.
   Google Scholar
• Kang S, Lucky AW, Pariser D et al, and the Tacrolimus Ointment Study Group, Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol (2001) 44: S58-64.
   Google Scholar
• Remitz A, for the European Tacrolimus Ointment Study Group, Superior flare prevention with 0.1%tacrolimus ointment in adult patients with moderate to severe atopic dermatitis. Proceedings from the 11th Congress of the European Academy of Dermatology and Venereology, Prague, Czech Republic, 2-6 October 2002.
   Google Scholar
• Breuer K, Mussler S, Kapp A, Werfel T, Staphylococcus (welts: colonizing features and influence of an antibacterial treatment in adults with atopic dermatitis. Br J Dermatol (2002) 147: 55-61.
   Google Scholar
• Hauk PJ, Leung .DYM, Tacrolimus(FK506): new treatment approach in superantigen-associated diseases like atopic dermatitis? J Allergy Clin Mumma' (2001) 107: 391-2.
   Google Scholar
• Drake L, Prendergast M, Maher R et al, The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis. J Am Acad ,Dermatol (2001) 44: S65-72.
   Google Scholar
• Rico MJ, Lawrence I, Tacrolimus ointment for the treatment of atopic dermatitis: clinical and pharmacologic effects. Allergy Asthma Proc (2002) 23: 191-7.
   Google Scholar
• Alaiti S, Kang S, Fiedler VC et al, Tacrolimus(FK506)ointment for atopic dermatitis: a phase I study in adults and children. J Am Acad Dermatol (1998) 38: 69-76.
   Google Scholar
• Undre NA, Green A, Harper J et al, Tacrolimus pharmacokinetics in paediatricpatients with moderate to severe atopic dermatitis after single and repeated application. Ann Dermatol Venereal (2002) 129: Abstract P0273.
   Google Scholar
• Fujisawa, data on file.
   Google Scholar
• Soter NA, Fleischer AB, Webster GF et al, Tacrolimusointment for the treatment of atopic dermatitis in adult patients: part IL safety. J Am Arad Dermatol (2001) 44: S39-46.
   Google Scholar
• Vieluf D, Ruzicka T, Complications and diseases associated with atopic eczema. In: Ruzicka T, Pryzbilla B, eds. Handbook of atopic eczema. Berlin: Springer Verlag, 1991: 54-79.
   Google Scholar
• Caro I, Gordon KB, West DP, and the Tacrolimus Ointment Study Group et al, Long-term safety of topically applied tacrolimus ointment in adult patients with atopic dermatitis. American Academy of Dermatology 60th Annual Meeting, New Orleans, LA, USA, 22-27 February 2002: Poster presentation P111.
   Google Scholar
• Paller A, Hanifin j, Eichenfield L et al, Tacrolimusointment monotherapy is a safe and effective treatment or atopic dermatitis long-term (more than 3 years). American Academy of Dermatology 61st Annual Meeting, San Francisco, CA, 21-26 March 2003: Poster presentation P24.
   Google Scholar
• Reitamo S, Rissanen J, Remitz A et al, Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol (1998) 111: 396-8.
   Google Scholar
• Naylor M, Elmets CA, Rico MJ, Zheng S, and the Tacrolimus Ointment Study Group, Treatment with topical tacrolimus is not associated with an increase innon-melanoma skin / cancers. The American Academy of Dermatology 60th Annual Meeting, New Orleans, LA, USA, 22-27 February 2002: Poster presentation P18.
   Google Scholar
• Frieling UM, Schaumberg DA, Kupper TS et al, A randomized, 12-year primary-prevention trial of beta carotene supplementation for nonmelanoma skin cancer in the physician's health study. Arch Dertnatol (2000) 136: 179-84.
   Google Scholar
• Aly R, Bacteriology of atopic dermatitis. Acta Dermato-vener(Stockholm) (1980) 92: S16-8.
   Google Scholar
• Pournaras CC, Lubbe J, Saurat JH, Staphylococcal colonization in atopic dermatitis treatment with topical tacrolimus(FK 506). J Invest Dermatol (2001) 116: 480-1.
   Google Scholar
• Remitz A, Kylltinen H, Granlund H, Reitamo S, Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions. J Allergy Clin Immunol (2001) 107: 196-7.
   Google Scholar
• Stalder JF, Fleury M, Sourisse M et al, Local steroid therapy and bacterial skin flora in atopic dermatitis. Br J Dermatol (1994) 131: 536-40.
   Google Scholar
• Fujisawa. Summary of product characteristics. Protopic(tacrolimus) 0.03%and 0.1% ointment. April 2002.
   Google Scholar
• Novartis. Elide!(pimecrolimus) cream 1% prescribing information. December 2001.
   Google Scholar
• Sato K, Sugibayashi K, Morimoto Y, Species differences in percutaneous absorption of nicorandil. J Pharm Sci (1991) 80: 104-7.
   Google Scholar
• Barry B, Dermatological formulations: percutaneous absorption, In: Drugs and the Pharmaceutical Sciences Vol 18. New York/Basel: Marcel Dekker Inc., 1 98 3: 138-45.
   Google Scholar
• Stiehm ER, Roberts RL, Kaplan MS et al, The effect of tacrolimus ointment on the immune system of children aged 2-12. American Academy of Dermatology 61st Annual Meeting, San Francisco, CA, 21-26 March 2003: Poster presentation P545.
   Google Scholar